Immunity to asexual blood stage malaria and vaccine approaches.
The development of a malaria vaccine seems to be a definite possibility despite the fact that even individuals with a life time of endemic exposure do not develop sterile immunity. An effective malaria vaccine would be invaluable in preventing malaria-associated deaths in endemic areas, especially amongst children less than 5 years of age and pregnant women. This review discusses our current understanding of immunity against the asexual blood stage of malaria - the stage that is responsible for the symptoms of the disease - and approaches to the design of an asexual blood stage vaccine.
Wipasa
Jiraprapa
J
The Cooperative Research Centre for Vaccine Technology, The Queensland Institute of Medical Research, Australia.
Elliott
Salenna
S
Xu
Huji
H
Good
Michael F
MF
D000276:Adjuvants, Immunologic; D000328:Adult; D000818:Animals; D000852:Anopheles / Q000469:parasitology; D000953:Antigens, Protozoan / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000502:physiology; D004912:Erythrocytes / Q000469:parasitology; D005260:Female; D000882:Haplorhini; D006790:Host-Parasite Interactions; D006801:Humans; D007111:Immunity, Cellular; D007113:Immunity, Innate; D007223:Infant; D007303:Insect Vectors / Q000469:parasitology; D008018:Life Cycle Stages; D008288:Malaria / Q000097:blood / Q000276:immunology* / Q000401:mortality; D017780:Malaria Vaccines; D008297:Male; D051379:Mice; D018512:Parasitemia / Q000276:immunology*; D010961:Plasmodium / Q000276:immunology* / Q000502:physiology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000401:mortality
D000276:Adjuvants, Immunologic; D000953:Antigens, Protozoan; D016207:Cytokines; D017780:Malaria Vaccines